A dual oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) protease inhibitor asunaprevir (formerly BMS-650032) and HCV NS4A inhibitor daclatasvir (BMS-790052) cleared the virus in one-third of genotype 1 prior null responders to prior interferon-based therapy, and both of those with genotype 1b, according to data published in the January 19, 2012, New England Journal of Medicine .
The U.S. Food and Drug Administration (FDA) and Gilead Sciences last week announ...
HIV RNA levels are the most significant factor predicting risk of HIV transmissi...
Oral HIV antibody testing is quick and convenient, but this method is not quite ...
Four pharmaceutical companies recently agreed to discount their prices on antire...
The U.S. Food and Drug Administration (FDA) last week announced revisions to the...
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immun...
The following table from the U.S. Centers for Disease Control and Prevention (CD...
Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major ...
Three companies developing direct-acting antiviral agents (DAAs) for hepatitis C...
An investigational adenovirus-based hepatitis C virus (HCV) vaccine induced sust...
Screening all people in the U.S. in the 46 to 66 year age group for hepatitis C ...
Hepatitis C patients who develop anemia during treatment with pegylated int...
Coinfection with hepatitis B virus (HBV) nearly doubled the risk of progression ...
HIV and hepatitis C virus (HCV) experts have issued preliminary recommendations ...
Expert panels that put together the Department of Health and Human Services anti...
Reported cases of gonorrhea rose slightly and syphilis declined somewhat during ...
Oral cancers caused by oncogenic human papillomavirus (HPV) -- the same virus th...
Ribavirin, a component of standard therapy for chronic hepatitis C, may also be ...